EPO and diabetes mellitus: A decrease in plasma volume, with resultant hemoconcentration, could contribute to the increase in hematocrit as observed in a previous study.24 However, an alternative explanation for erythropoiesis may be an effect of SGLT2 inhibition.25,26 In 10 diabetes patients with normal kidney function, dapagliflozin administration caused the concentration of EPO to increase until it peaked at 2–4 weeks of treatment.